Litigation Details for JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2023)

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2023)

Docket	2:23-cv-00018	Date Filed	2023-01-03
Court	District Court, D. New Jersey	Date Terminated	2025-02-06
Cause	35:271 Patent Infringement	Assigned To	Michael E. Farbiarz
Jury Demand	None	Referred To	Andre M. Espinosa
Parties	BIOPHORE PHARMA, INC.; CIPLA USA, INC.
Patents	10,092,525; 10,111,840; 10,137,095; 10,603,288; 10,709,671; 10,709,673; 10,709,674; 10,828,310; 10,849,860; 10,918,608; 10,966,939; 11,065,209; 11,096,905; 11,154,516; 11,160,795; 11,207,292; 11,311,498; 11,357,741; 11,400,055; 11,406,623; 11,446,258; 9,949,937; 9,956,183; 9,956,184; 9,956,185; 9,956,186
Attorneys	CHRISTINE INTROMASSO GANNON; MICHAEL T. HENSLEY
Firms	Midlige Richter LLC; Quinn Emanuel Urquhart & Sullivan, LLP
Link to Docket	External link to docket

Details for JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-03				External link to document
2023-01-03	1	Complaint	the ’184 patent”), 9,956,185 (“the ’185 patent”), 9,956,186 (“the ’186 patent”), 10,092,525 (“the ’525…’937 patent, the ’183 patent, the ’184 patent, the ’185 patent, the ’186 patent, the ’525 patent, the…’840 patent, the ’095 patent, the ’288 patent, the ’671 patent, the ’673 patent, the ’674 patent, the…’860 patent, the ’939 patent, the ’905 patent, the ’516 patent, the ’292 patent, the ’498 patent, and…’185 patent, the ’186 patent, the ’525 patent, the ’840 patent, the ’095 patent, the ’288 patent, the	External link to document

Litigation summary and analysis for: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2023)

Last updated: April 25, 2026

What Happened in JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC., 2:23-cv-00018?

Who sued whom and where?

• Plaintiff: Jazz Pharmaceuticals Research UK Limited
• Defendant: Teva Pharmaceuticals, Inc.
• Court / Case No.: U.S. District Court, case 2:23-cv-00018
• Year filed: 2023
• Forum specifics (division/state): Not provided in the input.

What is the litigation about (patent and product)?

No information was provided in the input identifying:

• the asserted patent(s),
• the drug / NDA-ANDA product at issue,
• the Orange Book listing relied on,
• the trigger event (e.g., Paragraph IV / 505(b)(2) / 505(j) posture),
• or the theory (infringement, invalidity, 271(e)(2), inequitable conduct, etc.).

Because the record elements required for a patent litigation analysis are not present, a complete and accurate litigation summary cannot be produced from the supplied material.

Procedural posture

No docket milestones, filings, or outcomes were provided in the input (e.g., complaint date, answer, claim construction, motion practice, Markman date, summary judgment, trial schedule, settlement, dismissal). Without those facts, procedural analysis is not possible.

Claims and defenses

No information was provided about:

• asserted claims (independent/dependent claim set),
• infringement contentions (claim chart themes, key limitations),
• defenses (non-infringement, invalidity grounds such as §§ 101/102/103/112, prosecution history estoppel, prior art references),
• or expert report themes.

Relief sought

No information was provided about:

• the requested injunctive relief,
• damages or enhanced damages claims,
• declaratory judgments on invalidity/non-infringement,
• or any requested fee shifting.

What would drive value in this case (patent-portfolio lens)?

A correct value-driving analysis requires at least:

• asserted patent numbers and filing/grant dates,
• remaining term and regulatory exclusivity constraints,
• whether the case centers on formulation, polymorph/crystal form, method-of-use, or delivery mechanism,
• and the defendant's paragraph number posture and product launch timing.

Those inputs are not present, so the drivers cannot be mapped to the case.

---

Key Takeaways

• The provided input identifies only the parties and the case number.
• A patent litigation summary and analysis cannot be completed because the required dossier facts (asserted patents, product/NDA-ANDA, procedural history, and claim/defense content) are not included.
• No actionable conclusions on infringement, validity, or likely settlement posture can be derived from the supplied information.

---

FAQs

1. What is the asserted patent in 2:23-cv-00018?
   Not provided in the input.

2. What product or drug is being challenged by Teva?
   Not provided in the input.

3. Is this an ANDA Paragraph IV case?
   Not provided in the input.

4. What procedural stage is the case in?
   Not provided in the input.

5. What is the likely outcome path (settlement vs. trial)?
   Not provided in the input.

---

References

[1] (No citable case record details were provided in the input text.)